Navigate today’s most pressing health industry challenges with a leading global expert by your side.
ACO utilization & cost evaluation
Healthcare cost modeling
Insurance risk assessment
Medicare plan selection solution
Healthcare risk adjustment
Pharmaceutical claims analytics
Meet growing needs for innovative insurance solutions while increasing operational health and improving compliance.
Property & casualty advisory services
Modern flood insurance program
Investment, advisory & trading services
Financial modeling & industrialization
Geographic rating insights
Premium comparison platform
Retirement & Benefits
Deliver on the promises of the past and create smart solutions for the future.
Pension administration & communication
Retirement benefits administration platform
Compensations & benefits
Benefit plan evaluation
Health & welfare benefits administration platform
Manage complex risks using data-driven insights, advanced approaches, and deep industry experience.
Auto policy underwriting
Software performance enhancement
Mortgage platform for investments & reinsurance
Solvency II reporting & compliance
This is a place where your ideas and insights make an impact. Where an independent, entrepreneurial spirit is an advantage. And where diversity of thought and experience makes us who we are.
Data-driven insight. Deep expertise. Transformative innovation. Since 1947, Milliman has delivered intelligent solutions to improve health and financial security.
The access challenges facing healthcare products are becoming more and more complex. With direct experience serving stakeholders across the U.S. healthcare system, we can help you understand the market, identify actionable insights, develop market-ready strategies, and execute to the top of your potential.
Our solutions are tailored to your needs, whether you’re focused on small molecule pharma, gene and cell therapies, rare disease, biosimilars, or medical devices.
Develop strategies and tactics that drive product access.
With expertise in payer, pharmacy benefit managers (PBM), and integrated delivery networks (IDNs), we can help you identify access opportunities specific to your products. We speak your customers’ language, informed by our industry knowledge and supported by unbeatable pharmacy and medical data.
Create the studies and evidence that support your value proposition.
Our cross-functional team of experts can help you advance your health economic or medical- affairs strategy, regardless of where your product is in its life cycle.
Navigate the ever-changing policy landscape.
From proposed rule to policy, our team of experts can help you understand the spirit, implementation, and potential impact of health policy. From your perspective or your customers’, we analyze relevant scenarios, driving toward actionable strategies and tactical response.
Creative experts who know access.
Our full-service agency uses a data-driven approach to identify opportunities and develop the strategies and tactics to unlock performance. Our clinicians, strategists, and creatives have extensive experience in launch-readiness planning and optimization for in-line products.
Thoughtful design for the patient experience.
Getting your therapies to patients requires successfully engaging a complex and highly regulated landscape. Whether you’re looking to establish a new distribution strategy, access mail-order distributors, work with a specialty pharmacy network, or pursue other pharma supply chain strategies, we can help.
Better assumptions to size the opportunity.
Our team of experts can help teams to size an opportunity and estimate how the U.S. healthcare system may impact an asset’s potential future revenue.
Claim line detail for medical and prescription drug claims and enrollment.
Artificial intelligence tools, such as machine learning, have the potential to improve healthcare operations, diagnosis detection and workflows.
The Inflation Reduction Act will have countless implications for all industry stakeholders and will alter the Medicare landscape in 2023 and beyond.
Regenerative and targeted therapies increase the need to accurately identify rare diseases, and increased specificity in diagnosis codes of the ICD-10 could help.
Since the start of the COVID-19 pandemic, influenza positivity rates have remained at the lowest levels documented in modern history.
Expanding the utility and consistency of existing claims-coding processes may offer a low-effort, high-value return for health economics and outcomes research.
This paper uses calendar year 2018 Medicare Advantage administrative claim data for enrollees aged 65 and older enrolled in plans with embedded dental coverage to determine the types of dental services used and the dental per…
When it comes to gene and cell therapies, there are a number of risks and benefits that payers should consider.
Gene and cell therapies are notable health care innovations that could reshape the way certain diseases are managed and treated.
This report evaluates alternative payment models that potentially could be instituted by healthcare payers and manufacturers.
This research paper examines the prevalence of rare diseases in a U.S.…
Ask the tough questions. We’re ready for them.